Galmed postpones shareholder meeting for quorum

Galmed Pharmaceuticals Ltd. (GLMD) convened its Annual General Meeting of Shareholders on September 2, 2026, but adjourned it for one day due to lack of quorum.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. (GLMD) convened its Annual General Meeting of Shareholders on September 2, 2026, but adjourned it for one day due to lack of quorum. The meeting will be reconvened on September 3, 2026 at 4:00 p.m. Israel time at Meitar Law Offices in Ramat Gan.

The company states that this report is incorporated by reference into its registration statements on Form S-8 and Form F-3. The report is signed by President and Chief Executive Officer Allen Baharaff.

Key Figures

Original meeting date: September 2, 2026 Reconvened meeting date and time: September 3, 2026, 4:00 p.m. Israel time Adjournment length: 1 day

3 metrics

Original meeting date September 2, 2026 Date the Annual General Meeting of Shareholders was first convened before adjournment

Reconvened meeting date and time September 3, 2026, 4:00 p.m. Israel time Scheduled date and time for the reconvened Annual General Meeting of Shareholders

Adjournment length 1 day Length of adjournment of the Annual General Meeting of Shareholders due to lack of quorum

Key Terms

Annual General Meeting of Shareholders, quorum, incorporated by reference

3 terms

Annual General Meeting of Shareholders financial

"On September 2, 2026, Galmed Pharmaceuticals Ltd. convened an Annual General Meeting of Shareholders"

quorum regulatory

"the Meeting was adjourned for one day to the same time and place due to lack of quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

incorporated by reference regulatory

"This Form 6-K is incorporated by reference into the Company’s Registration Statements"

FAQ

What did Galmed Pharmaceuticals Ltd. (GLMD) announce in this Form 6-K?

Galmed Pharmaceuticals Ltd. announced that its Annual General Meeting of Shareholders on September 2, 2026 was adjourned for one day due to lack of quorum and will be reconvened on September 3, 2026 at 4:00 p.m. Israel time at Meitar Law Offices in Ramat Gan.

When will GLMD reconvene its Annual General Meeting of Shareholders?

Galmed Pharmaceuticals Ltd. will reconvene its Annual General Meeting of Shareholders on September 3, 2026 at 4:00 p.m. Israel time at Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, Israel.

Why was Galmed Pharmaceuticals’ 2026 Annual General Meeting adjourned?

The Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. held on September 2, 2026 was adjourned for one day due to a lack of quorum, meaning insufficient shares were represented to conduct the meeting.

Where will GLMD’s reconvened 2026 shareholder meeting take place?

The reconvened meeting will take place at Meitar Law Offices, legal counsel to Galmed Pharmaceuticals Ltd., located at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

How does this Galmed Pharmaceuticals 6-K relate to its registration statements?

Galmed Pharmaceuticals Ltd. states that this report is incorporated by reference into its Form S-8 registration statements (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and its Form F-3 registration statements (Nos. 333-272722, 333-283241).

Who signed this Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K?

The report was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff, who is identified as the company’s President and Chief Executive Officer, dated September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:06 PM Accepted by SEC EDGAR 09/02/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 2, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) convened an Annual General Meeting of Shareholders (the “Meeting”), however, the Meeting was adjourned for one day to the same time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Thursday, September 3, 2026 at 4:00 p.m., Israel time at the at the offices of Meitar | Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241). 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: September 2, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer